VGX DNA vaccine primate study results to be presented at the AIDS Vaccine 2007 Conference

Blue Bell, PA – August 20, 2007 –

VGX Pharmaceuticals Inc. (VGX) announced today that there will be multiple presentations regarding its DNA vaccines for HIV and its patented CELLECTRA™ DNA Delivery technology at the AIDS Vaccine 2007 Conference to be held August 20-23 in Seattle, Washington, USA.

The presentations will be delivered by the Company's collaborators at the University of Pennsylvania. The investigators have observed that significant T-cell mediated immune responses were generated in non-human primates to VGX's HIV DNA vaccine candidates delivered with CELLECTRA™ device. Most notably, the monkeys immunized with VGX vaccines displayed HIV-specific T cell responses as much as 10-20 fold greater than those reported in the literature using other vaccine modalities, including DNA vaccines without electroporation. Induction of high levels of T cell immune responses, especially the CD8+ Killer T cell responses, has long been thought to be important for developing a successful vaccine for HIV.

DNA vaccines, comprising plasmid DNA encoding proteins from pathogens, allergens, and tumors, are being evaluated by many research scientists as prophylactic vaccines and therapeutic treatments for infectious diseases, allergies and cancer. The use of DNA as a means of vaccination offers potential benefits in protective efficacy, cross-strain applicability, development speed and manufacturing cost compared with conventional vaccines. DNA vaccines are known to be particularly effective in inducing killer T-cell responses which are an important ingredient in fighting infections.

VGX Pharmaceuticals is developing a new generation of DNA vaccines utilizing synthetic consensus sequences and antigens for key HIV, HCV, HPV, and Influenza proteins that offer coverage across different viral sub-types or taxonomic groups. Pre-clinical studies have shown that immunization of mice and non-human primates using the consensus DNA constructs for each virus elicits an immune response against multiple sub-types of the HIV, HCV, HPV, or influenza viruses respectively.

VGX Pharmaceuticals has initiated IND-enabling pre-clinical toxicology studies for three of its DNA plasmid-based product candidates. The candidates include vaccines for human papilloma virus for the treatment of cervical cancer (VGX-3100) and avian influenza (VGX-3400), and a therapeutic based on human growth hormone releasing hormone (VGX-3200) for cancer related cachexia. Investigational New Drug Applications (INDs) for the three products are expected to be filed in the first half of 2008.

Cautionary Factors That May Affect Future Results - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on www.vgxp.com as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals
VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection, which is in Phase II clinical trials, and PENNVAX™-B, a DNA vaccine for preventing HIV infection, which is in Phase I clinical trials. In addition, VGX is planning to initiate Phase I clinical studies for VGX-1027, its lead compound for inflammatory diseases. VGX's research pipeline includes a new generation of SynCon™ DNA vaccines and therapeutics as well as the CELLECTRA™ electroporator, a patented DNA delivery device. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:
Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com